Skip to main content
. Author manuscript; available in PMC: 2012 Oct 1.
Published in final edited form as: J Thromb Haemost. 2011 Oct;9(10):2009–2019. doi: 10.1111/j.1538-7836.2011.04491.x

Fig. 2. Antigen levels and activity of cFIX in immunocopetent hemophilia B mice from different AAV vectors after intramuscular injection.

Fig. 2

A. Time course of cFIX expression. Male C57BL/6 hemophilia B mice were injected with AAV2/1 (n=14), 2 (n=7), 2/5 (n=7), 2/7 (n=9), 2/8 (n=7), and 2/9-CMV-cFIX-WPRE (n=6) at the dose of 1×1011 GC intramuscularly. Levels of cFIX expression in plasma were followed for over 23 weeks after injection (mean ± SD). AAV2/8 vector generated statistically higher cFIX levels than all other serotype vectors at all time points, with one exception (AAV2/9, week 12). ANOVA, p<0.05. B. aPTT assays were performed on plasma samples from hemophilia B mice before and 4 weeks after i.m. injection with 1×1011 GC of AAV2/7, 2/8, and 2/9 vectors. aPTT for hemophilia B mouse plasma spiked in with different amount of purified cFIX protein (3.1% or 25%) and pooled mouse plasma from wild type male C57BL/6 mice were included as references (5µg/ml is presumed as 100%). † p<0.005; * p<0.001, two-tailed t-test.